Parve Swapnil, Aliakberova Gulnaz I, Gylmanov Albert A, Abdulganieva Diana I
Global Health Program, Western Connecticut Health Network, Danbury, CT; Section of Cardiology, Republican Clinical Hospital, Kazan, Russia.
Section of Cardiology, Republican Clinical Hospital, Kazan, Russia.
Rev Cardiovasc Med. 2017;18(2):82-87. doi: 10.3909/ricm0867.
The 5-fluorouracil, doxorubicin, and cyclophosphamide (FAC) regimen is widely used in the management of breast cancer. The common cardiotoxic effects of doxorubicin include congestive heart failure and left ventricular dysfunction, and those of cyclophosphamide include pericarditis, myocarditis, and congestive heart failure. It has been postulated that cardiotoxicity of 5-fluorouracil presents as coronary artery diseases (eg, angina). Cardiomyopathy is a common outcome following treatment with the FAC regimen. We report on a 52-year-old woman with cardiomyopathy following chemotherapy and radiation therapy. The patient did not respond well to b-blockers and angiotensin-converting enzyme inhibitors. After the addition of exogenous phosphocreatine, the patient's cardiac condition improved significantly.
5-氟尿嘧啶、阿霉素和环磷酰胺（FAC）方案广泛应用于乳腺癌的治疗。阿霉素常见的心脏毒性作用包括充血性心力衰竭和左心室功能障碍，环磷酰胺的心脏毒性作用包括心包炎、心肌炎和充血性心力衰竭。据推测，5-氟尿嘧啶的心脏毒性表现为冠状动脉疾病（如心绞痛）。FAC方案治疗后，心肌病是常见的结果。我们报告了一名52岁的女性，在化疗和放疗后出现心肌病。该患者对β受体阻滞剂和血管紧张素转换酶抑制剂反应不佳。添加外源性磷酸肌酸后，患者的心脏状况显著改善。
